Anti-TMEM119 antibody [28-3] - Microglial marker,Abcam,AB209064

Anti-TMEM119 antibody [28-3] - Microglial marker (ab209064) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-FoFr, IHC-Fr and IHC-P Anti-TMEM119 antibody [28-3] - Microglial marker (ab209064) was first used in a scientific publication in 2016 and has been cited over 139 times in peer reviewed journals. It's performance in IHC and Immunofluorescence in mouse samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-TMEM119 antibody [28-3] - Microglial marker (ab209064) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-TMEM119 antibody [28-3] - Microglial marker (ab209064) has been confirmed by IHC testing in TMEM119 knockout Mouse brain cells. Anti-TMEM119 antibody [28-3] - Microglial marker (ab209064) has 20 independent reviews from customers. Anti-TMEM119 antibody [28-3] - Microglial marker (ab209064) specifically detects TMEM119 (UniProt ID: Q4V9L6; Molecular weight: 27kDa) and is sold in a convenient trial size to enable initial testing (10 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Conjugation-ready, carrier free format available for antibody clone 28-3 - ab234501 . TMEM119 is a marker for microglia, the resident immune cells of the brain. In Alzheimer's disease (AD) research, TMEM119 is used to differentiate microglia from other brain-resident cells and infiltrating macrophages. Altered TMEM119 expression in AD brains reflects microglial activation and neuroinflammation, making it a valuable tool for studying the immune response and pathology in Alzheimer's disease. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents .